Literature DB >> 20695887

Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.

Chen-Hsiang Shen1, Yuan-Fang Wang, Andrey Y Kovalevsky, Robert W Harrison, Irene T Weber.   

Abstract

The structural and kinetic effects of amprenavir (APV), a clinical HIV protease (PR) inhibitor, were analyzed with wild-type enzyme and mutants with single substitutions of V32I, I50V, I54V, I54M, I84V and L90M that are common in drug resistance. Crystal structures of the APV complexes at resolutions of 1.02-1.85 Å reveal the structural changes due to the mutations. Substitution of the larger side chains in PR(V32I) , PR(I54M) and PR(L90M) resulted in the formation of new hydrophobic contacts with flap residues, residues 79 and 80, and Asp25, respectively. Mutation to smaller side chains eliminated hydrophobic interactions in the PR(I50V) and PR(I54V) structures. The PR(I84V)-APV complex had lost hydrophobic contacts with APV, the PR(V32I)-APV complex showed increased hydrophobic contacts within the hydrophobic cluster and the PR(I50V) complex had weaker polar and hydrophobic interactions with APV. The observed structural changes in PR(I84V)-APV, PR(V32I)-APV and PR(I50V)-APV were related to their reduced inhibition by APV of six-, 10- and 30-fold, respectively, relative to wild-type PR. The APV complexes were compared with the corresponding saquinavir complexes. The PR dimers had distinct rearrangements of the flaps and 80's loops that adapt to the different P1' groups of the inhibitors, while maintaining contacts within the hydrophobic cluster. These small changes in the loops and weak internal interactions produce the different patterns of resistant mutations for the two drugs.
© 2010 The Authors Journal compilation © 2010 FEBS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695887      PMCID: PMC2975871          DOI: 10.1111/j.1742-4658.2010.07771.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  53 in total

1.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model.

Authors:  A A Vaguine; J Richelle; S J Wodak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

Review 2.  HIV inhibitors: problems and reality.

Authors:  J Tözsér
Journal:  Ann N Y Acad Sci       Date:  2001-11       Impact factor: 5.691

3.  Covariation of amino acid positions in HIV-1 protease.

Authors:  Noah G Hoffman; Celia A Schiffer; Ronald Swanstrom
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

4.  "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.

Authors:  Philip Martin; John F Vickrey; Gheorghe Proteasa; Yurytzy L Jimenez; Zdzislaw Wawrzak; Mark A Winters; Thomas C Merigan; Ladislau C Kovari
Journal:  Structure       Date:  2005-12       Impact factor: 5.006

5.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

6.  Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease.

Authors:  E M Wondrak; J M Louis
Journal:  Biochemistry       Date:  1996-10-01       Impact factor: 3.162

Review 7.  Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice.

Authors:  N A Roberts; J C Craig; J Sheldon
Journal:  AIDS       Date:  1998-03-26       Impact factor: 4.177

8.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.

Authors:  G F Short; A L Laikhter; M Lodder; Y Shayo; T Arslan; S M Hecht
Journal:  Biochemistry       Date:  2000-08-01       Impact factor: 3.162

10.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

View more
  50 in total

1.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

2.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

3.  Room Temperature Neutron Crystallography of Drug Resistant HIV-1 Protease Uncovers Limitations of X-ray Structural Analysis at 100 K.

Authors:  Oksana Gerlits; David A Keen; Matthew P Blakeley; John M Louis; Irene T Weber; Andrey Kovalevsky
Journal:  J Med Chem       Date:  2017-02-28       Impact factor: 7.446

4.  Enthalpic Breakdown of Water Structure on Protein Active-Site Surfaces.

Authors:  Kamran Haider; Lauren Wickstrom; Steven Ramsey; Michael K Gilson; Tom Kurtzman
Journal:  J Phys Chem B       Date:  2016-06-02       Impact factor: 2.991

5.  Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.

Authors:  Arun K Ghosh; Bruno D Chapsal; Garth L Parham; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2011-07-29       Impact factor: 7.446

6.  Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Bruno D Chapsal; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem Lett       Date:  2012-02-02       Impact factor: 2.823

7.  Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism.

Authors:  Biswa Ranjan Meher; Yixuan Wang
Journal:  J Mol Graph Model       Date:  2012-10-13       Impact factor: 2.518

8.  Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.

Authors:  Arun K Ghosh; Jacqueline N Williams; Rachel Y Ho; Hannah M Simpson; Shin-Ichiro Hattori; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-10-24       Impact factor: 7.446

9.  Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.

Authors:  Arun K Ghosh; Zilei Xia; Satish Kovela; William L Robinson; Megan E Johnson; Daniel W Kneller; Yuan-Fang Wang; Manabu Aoki; Yuki Takamatsu; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2019-10-04       Impact factor: 3.466

10.  Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.

Authors:  Arun K Ghosh; W Sean Fyvie; Margherita Brindisi; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2017-11-24       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.